15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $673M | -$575M | 0.0% | -79.5% | -$472M | — | $421M |
| 2024 | $560M | -$569M | 0.0% | -95.7% | -$421M | — | $174M |
| 2023 | $434M | -$607M | 0.0% | -131.1% | -$519M | — | $214M |
| 2022 | $363M | -$707M | 0.0% | -178.6% | -$497M | — | $133M |
| 2021 | $351M | -$454M | 0.0% | -108.6% | -$412M | — | $308M |
| 2020 | $271M | -$187M | 0.0% | -121.8% | -$176M | — | $714M |
| 2019 | $104M | -$403M | 0.0% | -409.0% | -$370M | — | $434M |
| 2018 | $51M | -$198M | 97.8% | -721.2% | -$295M | — | $113M |
| 2017 | $3M | -$302M | 100.0% | -12593.5% | -$257M | — | $100M |
| 2016 | $133000 | -$246M | 0.0% | -186471.4% | -$171M | — | $161M |
| 2015 | — | -$146M | — | — | — | — | $94M |
| 2014 | — | -$60M | — | — | — | — | $24M |
| 2014 | — | -$73M | — | — | -$61M | — | $55M |
| 2013 | — | -$35M | — | — | — | — | $7M |
| 2012 | — | -$16M | — | — | — | — | $86M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $136M | -$185M | 0.0% | -124.3% | -$198M | — | $175M |
| Dec '25 | $207M | -$129M | 0.0% | -54.7% | -$101M | — | $421M |
| Sep '25 | $160M | -$180M | 0.0% | -106.9% | -$93M | — | $203M |
| Jun '25 | $166M | -$115M | 0.0% | -64.8% | -$111M | — | $176M |
| Mar '25 | $139M | -$151M | 0.0% | -102.9% | -$167M | — | $127M |
| Dec '24 | $165M | -$133M | 0.0% | -74.3% | -$79M | — | $174M |
| Sep '24 | $139M | -$134M | 0.0% | -94.6% | -$69M | — | $151M |
| Jun '24 | $147M | -$132M | 0.0% | -79.1% | -$79M | — | $481M |
| Mar '24 | $109M | -$171M | 0.0% | -151.9% | -$194M | — | $112M |
| Dec '23 | $127M | -$123M | 0.0% | -95.8% | -$86M | — | $214M |
| Sep '23 | $98M | -$160M | 0.0% | -148.0% | -$122M | — | $73M |
| Jun '23 | $108M | -$160M | 0.0% | -136.6% | -$130M | — | $102M |
| Mar '23 | $100M | -$164M | 0.0% | -153.3% | -$182M | — | $86M |
| Dec '22 | $103M | -$152M | 0.0% | -140.9% | -$117M | — | $133M |
| Sep '22 | $91M | -$245M | 0.0% | -248.1% | -$121M | — | $392M |
| Jun '22 | $89M | -$158M | 0.0% | -158.5% | -$108M | — | $160M |
| Mar '22 | $80M | -$152M | 0.0% | -170.9% | -$150M | — | $154M |
| Dec '21 | $83M | -$122M | 0.0% | -123.0% | -$70M | — | $308M |
| Sep '21 | $82M | -$73M | 0.0% | -110.0% | -$80M | — | $198M |
| Jun '21 | $87M | -$122M | 0.0% | -95.2% | -$85M | — | $291M |
How the market has priced RARE against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Ultragenyx Pharmaceutical Inc.'s revenue has grown 19.9% per year. These are computed facts, not advice.
As of FY2025, Ultragenyx Pharmaceutical Inc. reported — of total debt against $421M of cash.
In FY2025, gross margin was —, operating margin -79.5%, and net margin -85.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.